[ad_1]
The US Food and Drug Administration (FDA) has approved the world's first drug for the treatment of genetically-based cancer for children and adults.
The agency said in a statement yesterday that the new drug called Vitrakvi and is aimed primarily at genetic mutations of cancerous tumors, regardless of the type of disease or place of origin. She added that the drug is designed to treat adult patients with cancer and children with solid tumors or if the surgical removal of tumors is likely to lead to serious illness, and has not been reported. no alternative treatment or cases that have not responded to available treatments. Or capsules, and the other form of medicine especially syrup for children.
To test the safety and effectiveness of the drug, the FDA approval followed three clinical trials involving 55 patients, children and adults, with solid tumors and having no alternative treatment. The team monitored a total response rate of 75% for various types of solid tumors and these responses were permanent. The tumors, treated with drugs, included soft tissue uremas, a rare type of cancer that affects muscles, adipose tissue or fibrosis, as well as cancers of the salivary gland, thyroid, and lung. Fatigue, nausea, cough, constipation, diarrhea, dizziness and vomiting, increased blood levels, and two types of liver enzymes were the most common side effects of the new drug. The FDA advises pregnant or breastfeeding women not to take this new medicine because it could harm the fetus or newborn. "The approval of the release and the introduction of this drug is an important step in the treatment of cancer because it treats it from its source," said the commissioner of the US Food and Drug Administration, Scott Gottlieb. (Anatolia)
Source link
